Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSage Group Regulatory News (SGE)

Share Price Information for Sage Group (SGE)

Share Price is delayed by 15 minutes
Get Live Data
883.20    30.00 (3.52%)
Bid:
880.60
Ask:
881.40
Spread: 0.80 (0.091%)
Market Cap: £7.96b
SGE Live PriceLast checked at - London Stock Exchange

Intraday Sage Group Share Chart

Update on financial reporting

8 Dec 2022 07:00

RNS Number : 9821I
Sage Group PLC
08 December 2022
 

Update on financial reporting

 

8 December 2022

As announced in Sage's FY22 results on 16 November 2022, Sage intends to evolve its financial reporting by giving greater emphasis to underlying revenue and profit measures, and by amending the presentation of its regional reporting. These changes will be introduced in Sage's Q1 23 trading update, and will apply to Sage's future financial reporting. Further details are set out below.

To facilitate comparison with prior periods, the appendix to this announcement sets out key reporting figures for FY22 reflecting these changes. Sage's primary annual and interim financial statements and notes to the accounts will not be impacted.

Focus on underlying measures

In addition to statutory financial reporting measures, Sage also provides non-GAAP Alternative Performance Measures (APMs) including underlying and organic measures, to help assess financial performance. Underlying measures allow management and investors to understand the performance of the Group on a constant currency basis excluding recurring and non-recurring items, while organic measures also adjust for the impact of acquisitions and disposals[1].

Going forward, Sage will provide financial metrics and analysis including the breakdown of revenue by category, by strategic product portfolio and by region, together with Annualised Recurring Revenue (ARR), on an underlying basis alongside organic growth rates. Sage Business Cloud penetration and subscription penetration will also be provided on an underlying basis. Previously this information was provided primarily on an organic basis. Certain organic revenue and profit measures including recurring and total revenue by region will continue to be provided in the interim and full year results. 

Sage believes that these changes will enable a clearer understanding of both the organic and inorganic performance of the Group.

Change to regional reporting

Sage also intends to amend the presentation of its regional reporting, to reflect recent changes to the way in which the Group manages its operations. Going forward, Sage will report performance across the following regions: North America, comprising the US, Sage Intacct and Canada; UKIA, comprising Northern Europe (UK & Ireland) and Africa & APAC; and Europe, comprising France, Central Europe and Iberia.

 

Enquiries:

Sage:

+44 (0) 7721 599502

FGS Global:

+44 (0) 20 7251 3801

James Sandford, Investor Relations

Conor McClafferty

David Ginivan, Corporate PR

Sophia Johnston

 

 

APPENDIX - FY22 underlying measures[2]

 

Underlying measures (£m)

Q1 22

H1 22

Q3 22 YTD

FY 22

Recurring revenue by portfolio[3]

 

 

 

 

Cloud native

90

191

308

435

Cloud connected

190

385

589

842

Sage Business Cloud

280

576

897

1,277

Products with potential to migrate

117

228

343

426

Future Sage Business Cloud Opportunity

397

804

1,240

1,703

Non-Sage Business Cloud

35

70

105

142

Recurring revenue by region

 

 

 

 

North America

174

357

562

787

UKIA[4]

134

273

417

568

Europe

124

244

366

490

Recurring revenue by category

Software subscription

337

688

1,064

1,464

Other recurring

95

186

281

381

Total recurring revenue

432

874

1,345

1,845

Other revenue (SSRS)

31

61

84

104

Total revenue

463

935

1,429

1,949

Underlying operating profit

183

377

 

 

 

Annualised Recurring Revenue (ARR)

1,809

2,057

of which cloud native

 

448 

 

560 

 

Breakdown of revenue by region

 

Underlying measures (£m)

Recurring revenue

Total revenue

H1 22

FY 22

H1 22

FY 22

North America

US

305

674

323

704

of which Sage Intacct

102

231

105

237

Canada

52

113

54

115

UKIA

Northern Europe (UK & Ireland)

208

428

212

434

Africa and APAC

65

140

72

153

Europe

France

128

258

136

273

Central Europe

56

112

71

136

Iberia

60

120

67

134

 


[1] APMs including underlying and organic measures are defined in Appendix 1 (on pages 13 and 14) of Sage's FY22 full year results announcement, dated 16 November 2022.

[2] The figures set out above are provided at FY22 exchange rates. In line with Sage's APM definitions, they will be retranslated at current period exchange rates when reported as comparator figures during FY23, to enable the Group's performance to be assessed on a constant currency basis.

[3] As Other revenue (SSRS) now accounts for only 5% of total revenue, the breakdown of revenue by strategic product portfolio will only be provided on a recurring revenue basis going forward.

[4] United Kingdom, Ireland, Africa and APAC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFFAFFLDIIF
Date   Source Headline
30th Jun 20239:48 amRNSDirector/PDMR Shareholding
27th Jun 20235:16 pmRNSDirector/PDMR Shareholding
21st Jun 20239:00 amRNSDirector/PDMR Shareholding
6th Jun 202312:02 pmRNSBlock listing Interim Review
31st May 20234:55 pmRNSHolding(s) in Company
31st May 20234:50 pmRNSTotal Voting Rights
30th May 202310:10 amRNSDirector/PDMR Shareholding
19th May 20234:58 pmRNSDirector/PDMR Shareholding
19th May 20234:45 pmRNSHolding(s) in Company
17th May 20237:00 amRNSResults for the six months to 31 March 2023
28th Apr 20233:30 pmRNSTotal Voting Rights
31st Mar 20232:11 pmRNSDirector/PDMR Shareholding
31st Mar 202312:40 pmRNSTotal Voting Rights
27th Mar 20231:40 pmRNSDirector/PDMR Shareholding
6th Mar 20234:42 pmRNSHolding(s) in Company
28th Feb 20231:50 pmRNSTotal Voting Rights
17th Feb 20235:22 pmRNSDirector/PDMR Shareholding
17th Feb 20235:02 pmRNSDirector/PDMR Shareholding
14th Feb 20233:59 pmRNSDirector/PDMR Shareholding
13th Feb 20236:16 pmRNSPublication of Final Terms
9th Feb 20239:32 amRNSDirector/PDMR Shareholding
7th Feb 20239:46 amRNSDirector/PDMR Shareholding
3rd Feb 202312:14 pmRNSDirector Declaration
2nd Feb 20233:31 pmRNSResult of AGM
2nd Feb 20239:57 amRNSDirector Declaration
31st Jan 20233:35 pmRNSSage: Publication of Base Prospectus
31st Jan 20233:00 pmRNSTotal Voting Rights
23rd Jan 20234:58 pmRNSDirector/PDMR Shareholding
19th Jan 20237:00 amRNSTrading Update for the 3 months ended 31 Dec 2022
30th Dec 202211:15 amRNSTotal Voting Rights
15th Dec 202211:21 amRNSDirector/PDMR Shareholding
8th Dec 20225:40 pmRNSDirector/PDMR Shareholding
8th Dec 20227:00 amRNSUpdate on financial reporting
7th Dec 20226:00 pmRNSDirector/PDMR Shareholding
7th Dec 202210:12 amRNSNotice of AGM
6th Dec 20226:13 pmRNSDirector/PDMR Shareholding
6th Dec 20225:23 pmRNSDirector/PDMR Shareholding
6th Dec 202210:25 amRNSBlock listing Interim Review
1st Dec 202211:03 amRNSAnnual Financial Report
30th Nov 20222:00 pmRNSTotal Voting Rights
24th Nov 202210:00 amRNSNon-executive Director Appointment
18th Nov 20229:13 amRNSDirector/PDMR Shareholding
16th Nov 20227:00 amRNSResults for the year ended 30 September 2022
15th Nov 20227:00 amRNSNon-executive Director Appointment
31st Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202211:45 amRNSTotal Voting Rights
20th Sep 20227:00 amRNSInvestor and Analyst Event
31st Aug 20223:44 pmRNSTotal Voting Rights
30th Aug 20225:10 pmRNSSage completes Lockstep acquisition
24th Aug 20223:37 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.